Sjogren’s syndrome (SS) is a chronic inflammatory disease that often presents with decreased function of the lacrimal and salivary glands and is associated with lymphocytic infiltration of the exocrine glands, especially the lacrimal and lacrimal glands. Saliva causes dry eyes (keratoconjunctivitis dry) and dry mouth (xerostomia), SS can affect the extracellular systems of organs, including the skin, lungs, heart, kidneys and nervous system, menstrual and hematopoietic systems. Below we review the clinical presentation, assessment and diagnosis of interstitial lung disease (ILD) in SS., the criteria for the diagnosis and pathogenesis of SS and the treatment of SS-associated interstitial lung disease (IDL) (SSILD) are presented separately .

These criteria have not been developed for clinical practice, and not all patients are diagnosed with CV .

● Primary Sjogren’s disease – Primary Sjogren’s syndrome (PSS) is diagnosed only when all other systemic rheumatic diseases are excluded; they mainly affect women in the guava grade from 50 to 70. (See section “Diagnosis and Classification of Sjogren’s Syndrome.”

● Secondary Sjogren’s Syndrome: Secondary Sjogren’s Syndrome (SSE) refers to SS disease that is associated with another connective tissue disorder, most commonly inflammatory rheumatoid arthritis, but also includes systemic lupus erythematosus. systemic sclerosis, mixed connective tissue disease and myositis. EIE in patients with SES is assessed based on the primary rheumatic disease rather than rheumatic fever.

Segren often has multiple pulmonary manifestations because it is a manifestation of SES, highlighting the need for a multimodal approach to the treatment of people with pulmonary complications according to published practice guidelines Since up to 65% of asymptomatic patients with Sjogren’s syndrome will have abnormal images of the lungs, a pulmonologist can play an important role in diagnosing the syndrome as well as resolving possible pulmonary complications. after the initial detection of pulmonary disease – quadriplegia.

In patients with airway disorders, unspecified interstitial lung disease, and pulmonary lymphoproliferative diseases. situation: if the patient has a suspicion of pulmonary hypertension if the patient has unexplained shortness of breath after excluding pulmonary disease, and if the patient has a suspicion of heart damage. In Sjogren’s syndrome, it is recommended for patients with nonspecific interstitial lung disease, diffuse cystic lung disease, or lung lymphoma. followed by assessment of pulmonary complications of Sjogren’s syndrome such as interstitial lung disease, interstitial lung disease, bronchiolitis, bronchiectasis, and pulmonary lymphoma. Patients with lung disease have a lower quality of life and higher mortality than patients with PSS without lung disease. This review summarizes our current understanding of the pulmonary manifestations of PSS and covers the clinical management of this entity. Lymphoma was reported in 12% of patients with PSS. There is no lymphoid tissue organization in the normal lung parenchyma, but inflammatory conditions such as pSS and chronic exposure to various antigenic stimuli can cause lymphocyte hyperplasia, which can develop into BALT lymphoma. Clinical manifestations The clinical manifestations of PSS can be nonspecific and patients may present with shortness of breath, cough, sputum production, chest pain, and/or fever.